couldn't find much on the current HINT trial other than this:
Dr. John Fleming, a neurology professor at the University of Wisconsin School of Medicine and Public Health, said his first-round trial of the substance in 2009 showed promising clinical, immunological, and MRI results. Participants reported no significant side effects. http://tinyurl.com/3y4vbxl
As of August 2010, the Phase II study, "Helminth-induced Immunomodulation Therapy (HINT)," was recruiting 20 individuals with RRMS at the University of Wisconsin in Madison and the Marshfield Clinic. Participants will receive a dose of 2,500 ova (tiny eggs) in liquid form every two weeks. After this liquid is ingested, the eggs hatch and grow to the size of an eyelash within the digestive tract, but once in the large intestine, the body's immune system kills the larvae. The primary outcome measure is MS activity, as judged by the number of new gadolinium-enhancing lesions on serial MRI scans. The study is estimated to be completed in March 2011.http://msassociation.org/publications/s ... .story.asp
Definitely a squeamish factor but it has logical underpinnings. I could see a situation where the effects of CCSVI opens up the blood brain barrier and then depending on how reactive the immune system is, which could historically have been modulated by helminths, you either get inflammation and lesions or you don't.
“We look at it
like using live yeast
cultures in yogurt,”
said Dr. Fleming.
“The idea is to use
helminth eggs as a
probiotic, in other
words, a live agent
that may provide a
health benefit to patients.”
yeah, not really buying the "it's just like yogurt" argument....